2021 Annual Meeting | Industry Therapeutic Update from Novartis Pharmaceuticals Corporation: KESIMPTA® (ofatumumab) for Relapsing MS: Powerful Efficacy, Targeted Therapy, and Flexible Self-Administration
Program Materials
Program Evaluations
Event Timeline
No timeline events available at this time. |